-
Tytuł:
-
Oncopeptide MBOP Encoded by LINC01234 Promotes Colorectal Cancer through MAPK Signaling Pathway.
-
Autorzy:
-
Tang C; Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Zhou Y; Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Sun W; Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Hu H; Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Liu Y; Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Chen L; Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Department of Clinical Pharmacy, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.; Westlake Laboratory of Life Sciences and Biomedicine of Zhejiang Province, Westlake University, Hangzhou 310024, China.
Ou F; Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Zeng S; Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Lin N; Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Department of Clinical Pharmacy, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.; Westlake Laboratory of Life Sciences and Biomedicine of Zhejiang Province, Westlake University, Hangzhou 310024, China.
Yu L; Institute of Drug Metabolism and Pharmaceutical Analysis, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.; Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Department of Clinical Pharmacy, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
-
Źródło:
-
Cancers [Cancers (Basel)] 2022 May 09; Vol. 14 (9). Date of Electronic Publication: 2022 May 09.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Basel, Switzerland : MDPI
-
References:
-
Cell Oncol (Dordr). 2020 Jun;43(3):377-394. (PMID: 32130660)
Nat Rev Clin Oncol. 2020 Jan;17(1):11-32. (PMID: 31289352)
Mol Ther Nucleic Acids. 2020 Mar 6;19:168-178. (PMID: 31838274)
Biomed Pharmacother. 2019 Dec;120:109507. (PMID: 31590125)
J Hepatol. 2020 Nov;73(5):1155-1169. (PMID: 32461121)
Nat Biotechnol. 2019 Apr;37(4):420-423. (PMID: 30778233)
Mol Cancer. 2014 Jan 31;13:18. (PMID: 24479681)
J Oncol. 2019 Nov 30;2019:4216750. (PMID: 31885576)
BMC Bioinformatics. 2013;14 Suppl 2:S4. (PMID: 23369107)
Methods Mol Biol. 1999;112:531-52. (PMID: 10027275)
Clin Cancer Res. 2018 Apr 15;24(8):2002-2014. (PMID: 29386218)
Nucleic Acids Res. 2013 Apr 1;41(6):e74. (PMID: 23335781)
Mol Ther. 2020 Jun 3;28(6):1479-1493. (PMID: 32246902)
J Virol. 2000 Feb;74(3):1158-67. (PMID: 10627526)
Cancer Res. 2009 Feb 1;69(3):879-86. (PMID: 19176371)
Adv Sci (Weinh). 2020 Mar 11;7(10):1903233. (PMID: 32440474)
J Neuroinflammation. 2020 Jan 10;17(1):13. (PMID: 31924228)
Nucleic Acids Res. 2022 Jan 7;50(D1):D287-D294. (PMID: 34403477)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Nucleic Acids Res. 2018 Jan 4;46(D1):D823-D830. (PMID: 28977460)
Cancer Discov. 2018 Apr;8(4):428-443. (PMID: 29431699)
Expert Opin Ther Targets. 2007 May;11(5):589-99. (PMID: 17465719)
Clin Cancer Res. 2020 Jun 1;26(11):2693-2703. (PMID: 31932491)
Nat Rev Immunol. 2013 Sep;13(9):679-92. (PMID: 23954936)
Cell Death Dis. 2019 Feb 12;10(2):137. (PMID: 30755591)
Lancet Oncol. 2005 May;6(5):322-7. (PMID: 15863380)
Cancer Discov. 2015 Apr;5(4):358-67. (PMID: 25673644)
J Exp Clin Cancer Res. 2019 Dec 16;38(1):492. (PMID: 31842958)
J Exp Med. 2020 Mar 2;217(3):. (PMID: 31816634)
Mol Cancer. 2020 Feb 15;19(1):30. (PMID: 32059672)
Oncogene. 2007 May 14;26(22):3279-90. (PMID: 17496922)
J Hematol Oncol. 2020 Jan 20;13(1):7. (PMID: 31959200)
J Mol Biol. 2001 Jan 19;305(3):567-80. (PMID: 11152613)
Cancer Metastasis Rev. 2020 Dec;39(4):1143-1157. (PMID: 32648137)
EMBO Rep. 2020 Nov 5;21(11):e49305. (PMID: 32924251)
Nucleic Acids Res. 2017 Jul 3;45(W1):W12-W16. (PMID: 28521017)
Mol Cancer. 2019 Mar 29;18(1):47. (PMID: 30925892)
Nat Commun. 2020 Apr 3;11(1):1685. (PMID: 32245947)
Ther Adv Med Oncol. 2021 Feb 22;13:1758835921992974. (PMID: 33747149)
Nature. 2018 Sep;561(7724):556-560. (PMID: 30232453)
Curr Biol. 2010 Sep 28;20(18):1615-25. (PMID: 20832312)
-
Grant Information:
-
81973390 National Natural Science Foundation of China; 2021R52013 Ten-thousand Talents Program of Zhejiang Province
-
Contributed Indexing:
-
Keywords: LncRNA; MAPK signaling pathway; MBOP; colorectal cancer; peptide
-
Entry Date(s):
-
Date Created: 20220514 Latest Revision: 20220716
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC9100262
-
DOI:
-
10.3390/cancers14092338
-
PMID:
-
35565466
-
Colorectal cancer (CRC) ranks third in incidence rate and second in mortality rate of malignancy worldwide, and the diagnosis and therapeutics of it remain to be further studied. With the emergence of noncoding RNAs (ncRNAs) and potential peptides derived from ncRNAs across various biological processes, we here aimed to identify a ncRNA-derived peptide possible for revealing the oncogenesis of CRC. Through combined predictive analysis of the coding potential of a batch of long noncoding RNAs (lncRNAs), the existence of an 85 amino-acid-peptide, named MEK1-binding oncopeptide (MBOP) and encoded from LINC01234 was confirmed. Mass spectrometry and Western blot assays indicated the overexpression of MBOP in CRC tissues and cell lines compared to adjacent noncancerous tissues and the normal colonic epithelial cell line. In vivo and in vitro migration and proliferation assays defined MBOP as an oncogenic peptide. Immunoprecipitation trials showed that MEK1 was the key interacting protein of MBOP, and MBOP promoted the MEK1/pERK/MMP2/MMP9 axis in CRC. Two E3-ligase enzymes MAEA and RMND5A mediated the ubiquitin-protease-system-related degradation of MBOP. This study indicates that MBOP might be a candidate prognostic indicator and a potential target for clinical therapy of CRC.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.